NCT00836225View on ClinicalTrials.gov

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

January 31, 2012

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

ISIS 388626

"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"

Trial Locations (1)

Unknown

Center for Human Drug Research, Leiden